MENU
+Compare
ABBV
Stock ticker: NYSE
AS OF
Mar 28 closing price
Price
$205.29
Change
+$2.57 (+1.27%)
Capitalization
322.43B

ABBV stock forecast, quote, news & analysis

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta)... Show more

ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for ABBV with price predictions
Mar 28, 2025

ABBV sees its Stochastic Oscillator ascends from oversold territory

On March 28, 2025, the Stochastic Oscillator for ABBV moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 53 instances where the indicator left the oversold zone. In of the 53 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in of 365 cases, the price rose further within the following month. The odds of a continued upward trend are .

ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 371 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ABBV moved out of overbought territory on March 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on March 21, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ABBV as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on March 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (30.864) is very high in comparison to the industry average of (5.632). P/E Ratio (66.456) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.499) is also within normal values, averaging (3.004). Dividend Yield (0.033) settles around the average of (0.161) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (3.643).

A.I.Advisor
published Dividends

ABBV paid dividends on February 14, 2025

ABBVIE ABBV Stock Dividends
А dividend of $1.64 per share was paid with a record date of February 14, 2025, and an ex-dividend date of January 15, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was -7%. PTKFY experienced the highest price growth at 17%, while LYPHF experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -82%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was 1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 62
Price Growth Rating: 54
SMR Rating: 61
Profit Risk Rating: 74
Seasonality Score: 19 (-100 ... +100)
View a ticker or compare two or three
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a research-based pharmaceutical company

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1 North Waukegan Road
Phone
+1 847 932-7900
Employees
50000
Web
http://www.abbvieinvestor.com